Navigation Links
High-resolution imaging technology reveals cellular details of coronary arteries
Date:7/10/2011

Researchers at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) have developed a one-micrometer-resolution version of the intravascular imaging technology optical coherence tomography (OCT) that can reveal cellular and subcellular features of coronary artery disease. In a Nature Medicine paper receiving advance online publication, the investigators describe how microOCT which provides 10 times greater resolution than standard OCT was able to show individual arterial and inflammatory cells, including features that may identify vulnerable plaques, within coronary artery samples.

"MicroOCT has the contrast and resolution required to investigate the cellular and subcellular components underlying coronary atherosclerosis, the disease that precipitates heart attack," says Gary Tearney, MD, PhD, of the Wellman Center and the MGH Pathology Department, who led the study. "This high level of performance opens up the future possibility of observing these microscopic features in human patients, which has implications for improving the understanding, diagnosis and therapeutic monitoring of coronary artery disease."

A catheter-based technology, OCT uses reflected near-infrared light to create detailed images of the internal surfaces of blood vessels. Although the technology is already being used to identify arterial plaques that are likely to rupture, standard OCT can clearly image only structures larger than 10 micrometers (millionths of a meter). Using new types of lenses and advanced imaging components, microOCT is able to image structures as small as one micrometer, revealing in intact tissue the detailed information provided by the prepared tissue slides of traditional pathology much faster and in three dimensions.

The researchers describe how using microOCT to study human and animal coronary artery tissue revealed detailed images of:

  • endothelial cells that line coronary arteries,
  • inflammatory cells that contribute to the formation of coronary plaques,
  • smooth muscle cells that produce collagen in response to inflammation,
  • fibrin proteins and platelets that are involved in the formation of clots

MicroOCT also produced detailed images of stents placed within coronary arteries, clearly distinguishing bare-metal stents from those covered with a drug-releasing polymer and revealing defects in the polymer coating.

"When we are able to implement microOCT in humans probably in three to five years the 10 times greater resolution will allow us to observe cells in the coronary arteries of living patients," says Tearney, a professor of Pathology at Harvard Medical School. "The ability to track and follow cells in three dimensions could help us prove or disprove many theories about coronary artery disease and better understand how clots form on a microscopic level. Improved definitions of high-risk plaques will lead to greater accuracy in identifying those that may go on to rupture and block the coronary artery, and the ability to monitor healing around implanted devices like stents could reduce the number of patients who must be on anticlotting medications, which are expensive and have side effects."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert  

Related medicine news :

1. A new high-resolution method for imaging below the skin using a liquid lens
2. Neuroimaging study may pave way for effective Alzheimers treatments
3. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
4. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
5. Less is more in cancer imaging
6. Imaging manufacturers: Plan to reduce unnecessary radiation exposure and medical errors
7. National Council on Aging Releases Survey on Medical Imaging Safety
8. Artists, Product Designers, Printing Gurus, Game Developers, Manufacturing Engineers Will Converge at RAPID 2010/3D IMAGING Conference/Expo, May 18-20 in LA
9. Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
10. Imaging fat layer around heart can help predict disease
11. ModiFace Launches VuMe in Southern Florida – the World's First Full-Featured Touch-Screen Cosmetic Surgery Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High-resolution imaging technology reveals cellular details of coronary arteries
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology: